GlaxoSmithKline took the drug all the way through Phase II clinical trials in humans, successfully demonstrating that it lowered cholesterol levels without any problematic side effects.
To be eligible for the program, drugs would have to be at the end of Phase II trials or partway through Phase III, depending on the kind of drug and cancer involved.
This resulted in the formation of an LC and prepolymer region through phase separation.
Mixed phase α/β AgAl0.4Ga0.6O2 solid solution with heterojunction was fabricated through phase transformation.
Research groups that have progressed from pilot through Phase II/III clinical trials were analyzed.
Option (a) has progressed through phase I clinical trials with human butyrylcholinesterase.
A procedure was developed to fabricate these asymmetric films through phase inversion of BPS solutions.
Improvements in unitary gate fidelity are achieved through phase transient correction and hardware optimization.
When they compared fast- and slow-growing bones in the same animal, the researchers found that in slower-growing bones of the foreleg, cells went through phase one but stopped growing partway through phase two.
In this situation, the sidelobe suppression can be achieved by suppressing the ripples in band through phase predistortion.
Under normal condition, the voltage and current are synchronized with each other through phase lock loop (PLL).
